Kevin Kunzmann

The Gilead subsidiary will provide the authorized generic of sofosbuvir/velpatasvir for the state's at-risk patient population over 5 years.

There is currently no metric depicting the scope of health equity in the US, as common healthcare status metrics—morbidity and mortality—may not equate to a perfect representation of general population health.

The burdensome, inflammatory chronic condition is highlighted by difficult diagnoses and screening options. How is research advancing to improve care?

The CD38 monoclonal antibody has been approved in combination with lenalidomide and dexamethasone to treat patients ineligible for autologous stem cell transplant.

Last year, the FDA approved the drug as a novel therapy for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled for medical or dental procedure.

After showing the ability to regain patients' senses of smell and taste in a pair of phase 3 trials, the biologic becomes the first indicated for CRSwNP.

The NMDA receptor, in combination with rehabilitation, may serve as a powerful agent for reducing relapse rates.

Twirla, from Agile Therapeutics, has been seeking marketing approval from the FDA since 2012.

A new pooled cohort analysis supports the longheld threshold of < .70 FEV1:FVC ratio to indicate patient risks from COPD-related events.

Hypoactive sexual desire disorder is currently the most common form of sexual dysfunction among women in the US. There's also limited treatment options for it.

How advanced biologic care and symptom management programs fail patients more advanced in their disease.

A new retrospective cohort finds that patients with untreated obstructive sleep apnea face a two-fold greater risk of developing T2D.

The first-approved therapy for what clinicians once called the 'chronic' form of multiple sclerosis has changed standards of care.

Why biomarkers must be identified in patients with the progressive form of multiple sclerosis&mdash;and in what symptoms may those biomarkers best present.

The endothelin receptor antagonist has proven benefits and safety for PAH patients burdened with liver or extrahepatic disease risks.

A team from Johns Hopkins assessed pediatric patients in Baltimore&mdash;an area with severe rates of asthma, indoor air pollution, and poor diets.

A three-arm clinical trial of the SAMBA program showed that screening for and tailoring to individuals' asthma needs improves their condition management.

A new study shows patients with T1D and comorbid cardiovascular disease face a signficantly greater cost of care.

A new study from ADA showed the investigative monoclonal antibody suppressed development and diagnosis of T1D in at-risk patients.

A new retrospective cohort analysis found that patients with type 2 diabetes generally have about 12 months following BI initiation to achieve A1c < 7.0%.

Type 2 diabetes patient outcomes including heart failure, stroke, and myocardial infarction were weighed between the 2 popular drug classes.

A study of the massive 2005 trial data found that fenofibrate-targeted biomarkers are closely associated to cardiovascular risks in patients with T2D.

The longest clinical assessment of a GLP-1 receptor agonist for cardiovascular outcomes showed a 12% decrease in MACE versus placebo.

An age-stratified analysis of Swedish national registry data found that myocardial infarction and heart failure rates may even be more prevalent in patients with T1D.

It's been 5 years since the FDA approved empagliflozin, and 4 since the major outcomes findings. What is its role in diabetes care today?

The three-year trial reported that initial weight loss plus 1 of any 4 diet and exercise programs is associated with major benefits for at-risk patients.

A review of REDUCE-IT data prior to an FDA supplemental new drug application decision shows the unprecedented benefit of the fish oil therapy.

New findings show the controversial 2018 blood sugar control recommendations are associated with cost benefits for 3 subgroups of affected T2D patients.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

New trial results show the cytotoxin delivers clinical responses in patients with untreated or relapsed forms of the rare disease.